Publications by authors named "Silvana Ruffolo"
Article Synopsis
- The study focuses on gender differences in the treatment and effects of psoriasis, highlighting that women report a greater negative impact on quality of life and lower satisfaction with treatment compared to men.
- The CANOVA study involved 669 psoriasis patients from 17 Italian clinics and assessed the effectiveness of biologic treatments over different time periods.
- Findings indicate that while biologics are effective for both genders, women experience a more significant reduction in quality of life and express lower satisfaction with their treatment options.
COVID Vaccine Arm (CVA) is an adverse drug reaction from mRNA vaccine for SARS-CoV-2. CVA is characterized by erythema and edema on the vaccination site (usually deltoid area) that appears from 5 to 10 days after vaccination and is sometimes associated with itching or pain. The exact etiology of CVA is still unclear, but delayed hypersensitivity against an excipient seems to play an essential role in the pathogenesis of the disease.
View Article and Find Full Text PDFEffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included.
View Article and Find Full Text PDFArticle Synopsis
- Psoriasis is a chronic inflammatory skin disease that can severely affect quality of life and is associated with various comorbidities, leading to increased healthcare costs.
- The CANOVA study evaluated the cost-effectiveness of several biologic treatments for moderate-to-severe plaque psoriasis in Italy, focusing on direct costs and effectiveness based on response rates.
- Among the biologics, secukinumab was found to have the highest response rate and the lowest cost per sustained response, while the originator adalimumab had the best cost per responder ratio, indicating variations in cost-effectiveness among the treatments.